Genentech has revealed negative results from the IMblaze370 study, a Phase III trial investigating Tecentriq (atezolizumab) in combination with Cotellic (cobimetinib) to treat patients with heavily pre-treated, locally advanced or metastatic colorectal cancer (CRC).

The multi-centre, open-label, three-arm, randomised trial enrolled 363 people with difficult-to-treat locally advanced or metastatic colorectal cancer who have received at least two prior regimens of chemotherapy for metastatic disease.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It also compared a standard of care therapy regorafenib with Cotellicplus Tecentriq and Tecentriq monotherapy.

During the trial, patients were randomised at 2:1:1 ratio to receive Tecentriq plus Cotellic, or Tecentriq, or Regorafenib.

Patients in the combination arm received Cotellicon days one to 21 plus Tecentriq on day one and day 15 in a 28-day cycle.

Participants in the monotherapy arm received Tecentriq on day one of each 21-day cycle, while those in the control arm received regorafenib on days one to 21 in a 28-day cycle, until loss of clinical benefit.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“We have a number of studies evaluating medicines in colorectal cancer that could play an important role in the treatment of people with this disease in the future.”

The trial’s primary endpoint was overall survival, while key secondary endpoints comprised progression-free survival (PFS), overall response rate (ORR) and duration of response (DoR).

The trial was unable to meet its primary endpoint of overall survival (OS) compared to regorafenib.

Genentech chief medical officer and global product development head Sandra Horning said: “While these results are not what we hoped for, we remain committed to applying our deep experience to develop medicines that will improve outcomes for people living with gastrointestinal cancers.

“In particular, we have a number of studies evaluating medicines in colorectal cancer that could play an important role in the treatment of people with this disease in the future.”

Genentech expects to further evaluate the results from IMblaze370 and present them at an upcoming medical meeting.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact